· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
August 6, 2014
Dear Health Care Professional
Subject: ARZERRA™ (ofatumumab) – Fatal infusion reaction reported in a patient with Chronic Lymphocytic Leukemia (CLL) who received intravenous ofatumumab
GlaxoSmithKline Inc. (GSK), in consultation with Health Canada, would like to inform you of important new safety information regarding a fatal infusion-related reaction following the use of ARZERRA™ (ofatumumab).
ARZERRA™ is an anti-CD20 antibody that is authorized in Canada under a Notice of Compliance with conditions, for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
Health care professionals should inform their patients regarding the risk of fatal infusion reactions associated with the use of ARZERRA™ (ofatumumab).
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious hypersensitivity or infusion reactions or other serious or unexpected adverse reactions in patients receiving ARZERRA™ should be reported to GlaxoSmithKline Inc. or Health Canada.
The revised Product Monograph may be accessed on the Health Canada Web site, or on the Canadian Web site of GlaxoSmithKline.
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374
To correct your mailing address or fax number, contact GlaxoSmithKline Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
If you have any questions about this new information, please contact GlaxoSmithKline Medical Information Department at 1-800-387-7374.
Sincerely,
original signed by
Dr. Sally Taylor
Country Medical Director, Canada
GlaxoSmithKline Inc.
™ARZERRA is used under license by GlaxoSmithKline Inc.